Topas Therapeutics today announced that it will present clinical Phase 2a data on its lead candidate, TPM502, in celiac ...

Bioxodes announces positive Phase 2a interim data for BIOX-101 in intracerebral hemorrhagic stroke patientsPrimary endpoint met, no drug-related serious adverse events Positive hematoma and edema ...

A phase 2a clinical trial of NEO100-01 is continuing to recruit patients with malignant gliomas, with full enrollment ...

Statistically significant improvements observed across clinical endpoints; final cohort results expected in Q2 2025 ...

Verastem Oncology (NASDAQ:VSTM) announced on Wednesday that the U.S. FDA has cleared the investigational new drug application ...

In a Phase 1b/2a trial for lymphoma and cytokine release syndrome, the first group's dose-limiting toxicity observation ...

Complete resolution of lung metastasis confirmed at 4 month follow-up in hormone receptor positive (HR+) breast ...

Full abstracts will be released by ASCO on Thursday, May 22, 2025, at 5:00 PM ET. Details from the presentations will be available following the event on the Candel website at Candel Media. * Dr.

Hoth Therapeutics (HOTH) announced positive interim data from the open-label portion of its Phase 2a clinical trial, CLEER-001, evaluating ...

Session: Rapid Oral Abstract Sessions: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology ...

Q32 previously announced results from Part A of the SIGNAL-AA Phase 2a clinical trial, a randomized, double-blind, placebo-controlled, multi-center clinical trial evaluating bempikibart in adult ...